Interestingly, when dichotomizing a cohort of 68 PDAC patients according to primary tumor cell C/EBPγ expression, patients with high C/EBPγ expression did not experience a decreased survival but rather a prolongation of 7.52 months compared to patients with low C/EBPγ expression, although this difference lacks significance. The gene discussed is CEBPG; the disease is neoplasm.